Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track ADXN with free AI briefings, catalyst countdowns, and dilution alerts.

ADXN · Addex Therapeutics Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$767,328 Cash on Hand

3.9mo Cash Runway

Follow ADXN by email Get an email when ADXN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ADXN, unsubscribe in one click. Privacy

📣 What ADXN Says Is Next

fourth quarter of 2027 · “The Group expects that its existing cash and cash equivalents at the issuance date of these unaudited interim condensed consolidated financial statements will be sufficient to fund its operations and meet all of its obligations as they fall due through the fourth quarter of 2027.”
Company press release, Sep 28, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

Oct 2022 · Phase 2 · Results Expected · Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharosp
Registry primary completion date, not a results date
Feb 2012 · Phase 2 · Results Expected · ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Dis
Registry primary completion date, not a results date
Dec 2009 · Phase 2 · Results Expected · ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesop
Registry primary completion date, not a results date
Oct 2009 · Phase 2 · Results Expected · ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Dipraglurant	Parkinson Disease	Phase 2/3 · NCT05116813	Terminated
ADX10059	Gastroesophageal Reflux	Phase 2 · NCT00810485	Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ADXN holds $767,328 in cash and short-term investments and burns about $596,668/quarter from operations, an estimated runway of 3.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 87 · High

Cash runway 4 months +40
ATM program on file since Dec 2025 +15
Shelf registration (F-3, Nov 2025) +10
Going-concern doubt in the latest 20-F +15As stated in Note 4, these events or conditions, along with other matters as set forth in Note 4, raise substantial doubt about the Group’s ability to continue as a going concern. 20-F, May 2026
Share count +15% in a year +7

Recent financing filings on SEC EDGAR:

Dec 10, 2025 · ATM program, up to $3M · 424B5
Nov 19, 2025 · Shelf registration, up to $150M · F-3
Jan 30, 2024 · ATM program, up to $2M · 424B5

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADXN files for a raise →

👥 Who Owns ADXN

Insiders 15.1% Institutions (2 holders) 0% Public and other holders 84.9%

Holder	Type	Shares	% of shares	As of
Timothy Mark Dyer CHIEF EXECUTIVE OFFICER, Director · +3.37M options	Insider	16,848,979	11.40%	2026-09-02
Vincent Michael Lawton Director · +501,598 options	Insider	2,507,987	1.70%	2026-09-02
Raymond George Hill Director · +273,107 options	Insider	1,365,532	0.92%	2026-09-02
Roger Mills CHIEF MEDICAL OFFICER, Director · +50,000 options	Insider	785,976	0.53%	2026-09-02
Mikhail Kalinichev HEAD OF TRANSLATIONAL SCIENCE · +200,000 options	Insider	306,765	0.21%	2026-09-02
Jason Raleigh Nunn Director · +50,000 options	Insider	219,561	0.15%	2026-09-02
Isaac Manke Director · +50,000 options	Insider	219,561	0.15%	2026-09-02

Share count 147,831,814 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ADXN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADXN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z